tbuckley/cabot-search huggingface dataset:
P68 * UNRAVELLING GRADE 3 GLIOMAS
Authors: R. K. Mathew, E. Goacher, D. Bhargava, A. Chakrabarty, P. Roberts, J. Goodden, C. Loughrey, P. D. Chumas
Journal: Neuro-Oncology (2014)

INTRODUCTION: Patients diagnosed with WHO Grade III Gliomas experience huge variations in overall survival and treatment response. In general, Grade II and Grade IV gliomas behave more predictably. We have attempted to identify factors within grade III gliomas that may better inform clinicians about the prognosis of this heterogeneous group of tumours. METHOD: Retrospective (1988-2013) case note, database, cytogenetic and tissue sample review of patients histologically diagnosed with WHO Grade III Gliomas. Demographics, molecular data (1p19q co-deletion, IDH mutation, Ki67/MIB), percentage of Grade II features and overall survival (OS) was analysed. Mortality was defined as any cause of death within 12, 18, 24, 36, 48 and 60 months of diagnosis. Results were statistically analysed by Kaplan-Meier and Log Rank (Cox Proportional Regression Hazard) Testing (p < 0.05). RESULTS: Patients (n = 158) had a mean age of 46 years (range 6 days-77 years) with 54% male and 46% female. Mean OS was 25.2 months (range 0-125 months). Diagnoses were 78.5% astrocytoma, 9.5% oligoastrocytoma, 10.1% oligodendroglioma and 1.9% other. Debulking (versus biopsy), adjuvant therapy, age <50 years, 1p19q co-deletion, and intermediate proliferation rate (10-20%) significantly improved OS. Late OS (>48 months) was better for females. Tissue analysis for percentage Grade II features is ongoing. CONCLUSION: Debulking surgery, adjuvant therapy and age are well-established prognostic indicators. Molecular factors are possibly more weighted factors in predicting tumour behaviour and outcome. Routine availability of molecular genetics and the percentage of Grade II features will likely redefine this group of tumours into subcategories.
Voluntary Running Suppresses Tumor Growth through Epinephrine- and IL-6-Dependent NK Cell Mobilization and Redistribution
Authors: Line Pedersen, Manja Idorn, Gitte H. Olofsson, Britt Lauenborg, Intawat Nookaew, Rasmus Hvass Hansen, Helle Hjorth Johannesen, Jürgen C. Becker, Katrine S. Pedersen, Christine Dethlefsen, Jens Nielsen, Julie Gehl, Bente K. Pedersen, Per thor Straten, Pernille Hojman
Journal: Cell Metabolism (2016)
Clinical impact of ERCC1 and TOPOIIα gene expression in small-cell lung cancer patients treated with platinum/etoposide
Authors: G. Selvaggi, P. Ceppi, M. Longo, M. Giaj Levra, S. Cappia, M. Volante, S. Novello, M. Papotti, G. V. Scagliotti
Journal: Journal of Clinical Oncology (2007)

2526 Background: Platinum/etoposide is a commonly used regimen both in limited (LS) and extensive stage (ES) small-cell lung cancer (SCLC). The study was aimed at testing retrospectively the predictive role of mRNA quantification of genes correlated to platinum/etoposide therapy: ERCC1, RRM1 and TOPOIIa. Methods: Total RNA was extracted from microdissected sections of 103 formalin-fixed, paraffin embedded bronchial biopsies. Relative quantification for ERCC1, RRM1 and TOPOIIa and an internal reference gene (β- Actin) was performed by Real-Time PCR using intron-spanning primers. ERCC1 expression was also evaluated by immunohistochemistry using a semi-quantitative score. Results: Eighty-five samples (83%) were successfully amplified. Overall median survival (MS) was 9.9 months, 45 patients had LS (MS=13.1 months) and 40 had ES (MS=7.1 months). Fifty-six (65%) had an objective (complete or partial) response to treatment. Immunohistochemical staining of ERCC1 evidenced a positivity in 2 out of 85 patients with no correlation with clinico-pathological factors. By contrast, a gene expression level was detectable in all samples and a significant correlation between ERCC1 and RRM1 levels (R s =0.34, p=0.0011) was found. By segregating patients according to response to treatment, it was found that lower TOPOIIa expression was associated to a better response in LS patients (p=0.025) and, more interestingly, those who had a complete response had low TOPOIIa levels than both partial and non-responsive patients (p=0.015). By adopting cut-offs according to median values, univariate analysis of survival by Kaplan-Meier method showed that LS patients with low ERCC1 had a significantly longer survival (MS 14.9 vs. 9.9 months, p=0.012), while RRM1 and TOPOIIa levels showed no influence on outcome. In multivariate analysis, ERCC1 was an independent prognostic factor for survival of LS patients, together with PS and response to therapy. No significant role was found for ERCC1, RRM1 and TOPOIIa in patients with ES. Conclusions: ERCC1 and TOPOIIa represent reliable candidate markers in predicting clinical outcome and response to treatment in LS SCLC patients, who may benefit from a better individualized therapy. [Table: see text]
False-Positive Axillary Lymph Nodes Due to Silicone Adenitis on 18 F-FDG PET/CT in an Oncological Setting
Authors: Ludovic D’hulst, Daniël Nicolaij, Laurence Beels, Olivier Gheysens, Herwig Alaerts, Christophe Van de Wiele, Alex Maes
Journal: Journal of Thoracic Oncology (2016)
Factors in Association Between Parkinson Disease and Risk of Cancer in Taiwan
Authors: D. Michal Freedman, Ruth M. Pfeiffer
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
MO19390 (SAiL): Incidence and management of hypertension (HTN) during bevacizumab (Bv)-based first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)
Authors: P. Garrido Lopez, J. Laskin, G. Jiang, F. Barlesi, D. Isla, C. Tsai
Journal: Journal of Clinical Oncology (2009)

e19002 Background: SAiL is an ongoing, multicenter, international, open-label trial investigating the safety and efficacy of first-line Bv in combination with a range of standard first-line chemotherapy regimens in &gt;2,000 pts with advanced NSCLC. Methods: Eligible pts had locally advanced, metastatic or recurrent non-squamous NSCLC. Pts received Bv (7.5mg/kg or 15mg/kg q3w) with standard first-line chemotherapy for up to 6 cycles, then Bv monotherapy until disease progression. Pts with uncontrolled HTN (systolic &gt;150mmHg and/or diastolic &gt;100mmHg) or active cardiovascular disease at baseline were excluded. The primary endpoint was the incidence of serious adverse events (SAEs) related to Bv, and AEs of special interest, including hypertension. Bv was interrupted for persistent or symptomatic grade 3 HTN and discontinued if blood pressure remained uncontrolled by medication. Bv was discontinued for grade 4 hypertension. Results: This analysis was based on 2,008 pts who received at least 1 dose of study medication (data cut-off July 2008): median age was 59 and ECOG PS 0/1/2 (%) was 38.1/56.1/5.8. Antihypertensive medications at baseline included ACE inhibitors (11.3%), Angiotensin II receptor blockers (6.2%), beta-blockers (10.9%), calcium channel blockers (7.7%) and diuretics (8%). Pts received a median of 5 Bv cycles and 4 chemotherapy cycles. Overall, 388 patients (19.3%) had a total of 487 incidents of HTN (any grade), occurring equally in patients ≤65 and &gt;65 years of age (18.9% and 20.2%, respectively). Only six pts (0.3%) had grade ≥3 HTN events related to Bv meeting the criteria for SAE. The overall incidence of HTN was consistent across the various types of chemotherapy regimens. Conclusions: The incidence of grade ≥3 HTN was low, and the overall HTN incidence was similar across age groups and chemotherapy regimens. Updated results will be presented, including data on HTN management and evolution of HTN events during administration of antihypertensive medication. [Table: see text]
The Presence of Minimal Residual Disease Pre- and Post-Transplant Is Predictive of Outcome in Recipients of Allogeneic Transplantation for Acute Myeloid Leukaemia.
Authors: Fiona L Dignan, Chloe Anthias, Mark E Ethell, Ricardo Morilla, Alison Morilla, Faith E Davies, Gareth J Morgan, Michael N Potter, Bronwen E Shaw
Journal: Blood (2009)
Long-term survival after alternative donor transplantation in children with acute leukemia.
Authors: Chelsea Lee Collins, Kwang Woo Ahn, Zhiwei Wang, Mary Eapen
Journal: Journal of Clinical Oncology (2013)

10006 Background: Most reports describing long-term survival after allogeneic transplantation are in adults after transplantation of bone marrow (BM) from HLA-matched siblings. This report compares long-term survival after transplantation of unrelated donor BM to that after umbilical cord blood (UCB) in children with acute leukemia. Methods: Included were patients aged less than 18 years with acute myeloid or lymphoblastic leukemia, alive and leukemia-free for at least 1 year after transplantation. Transplants occurred 2000-2009. Patients received BM grafts that were HLA-matched (N = 205) or mismatched at 1-HLA locus (N = 112) and UCB grafts that were matched (N = 55) or mismatched at 1 (N = 160) or 2 HLA-loci (N = 134). Multivariate Cox regression models were constructed to explore differences in survival between groups. UCB transplants were treated as a single group as there were no significant differences between HLA-matched and mismatched UCB grafts. Multivariate models held 3 treatment groups: HLA-matched BM, HLA-mismatched BM and UCB grafts. Results: The disease characteristics of the three groups were similar. There were differences in patient and transplant characteristics. Recipients of UCB transplants were younger, more likely non-Caucasian, and more likely to have received a non-irradiation-containing conditioning regimen, in-vivo T-cell depletion and GVHD prophylaxis with cyclosporine and either prednisone or mycophenolate. In multivariate analysis, the risks of long-term mortality were not significantly different after UCB and HLA-matched BM transplants (HR 0.83, p=0.41). Mortality risks were significantly higher after HLA-mismatched BM transplants compared to UCB (HR 1.66, p=0.03) and HLA-matched BM transplants (HR 2.00, p=0.008). In this cohort, surviving disease-free at least 1-year after transplantation, the 8-year probabilities of overall survival after UCB, HLA-matched and HLA-mismatched BM transplants were 78%, 81% and 68%. Conclusions: This is the first report to document long-term durability of UCB grafts. The data continue to support the use of UCB grafts either in the absence of an HLA-matched donor or when transplantation is needed urgently for children with acute leukemia.
Prevalence of lymphedema and upper-limb impairments after axillary lymph node dissection or sentinel lymph node dissection in breast cancer: A 2-year follow-up study.
Authors: A. Sagen, R. Kåresen, M. J. Hjermstad, M. Risberg
Journal: Journal of Clinical Oncology (2010)

9137 Background: Arm lymphedema and limb morbidity in patients going through axillary lymph node dissection (ALND) or sentinel lymph node dissection (SLND) were investigated pre-operatively and after two years. Aims: to evaluate possible differences in arm morbidities between groups and to examine changes over time within groups. Methods: Two prospective female cohorts (n=393) treated with primary breast cancer surgery with ALND (n=204, mean age 55 ±10) or SLND (n=189, mean age 57 ±10) were examined for arm lymphedema (ALE), defined as > 10% increased arm volume relative to control arm volume, grip strength (kg), shoulder function, shoulder abduction endurance (sec) and BMI (kg/m2). Arm pain and sensation of heaviness in the affected arm was assessed on a 100 mm visual analogue scale (VAS). Descriptive statistics, t-tests and ANCOVA were employed. Results: Of the 393 women, 314 (80%) participated at the two-year follow-up (ALND n=152, SLND n=162). The number of patients with impairments was significantly higher (P< 0.05) in the ALND group after two years; 15 % had developed ALE, 36% reported pain and 32% had a sensation of heaviness, relative to 2% with ALE, 16% with pain and 2% with a sensation of heaviness in the SLND group. There were no significant differences between groups in shoulder function. Grip strength and shoulder abduction endurance in the affected limb significantly decreased from baseline to follow-up in the ALND group with mean reduction of 2.2 kg (CI 1.28-3.03) and 17 sec (CI 5.46- 28.60) (P< 0.05) respectively, while no significant decreases were observed in the SLND group. Both groups had a significant increase in BMI, but with less than 1 unit BMI (P< 0.05). Conclusions: Upper limb impairments two years after breast cancer surgery with ALND were significantly more prevalent compared to SLND surgery. Furthermore, there were significant decreases in grip strength and shoulder abduction endurance in the ALND group only. The ALND group may benefit from post-operative physical therapy focusing on muscle strength and endurance exercises. No significant financial relationships to disclose.
Visual Prognosis in USH2A-Associated Retinitis Pigmentosa Is Worse for Patients with Usher Syndrome Type IIa Than for Those with Nonsyndromic Retinitis Pigmentosa
Authors: Laurence H.M. Pierrache, Bas P. Hartel, Erwin van Wijk, Magda A. Meester-Smoor, Frans P.M. Cremers, Elfride de Baere, Julie de Zaeytijd, Mary J. van Schooneveld, Cor W.R.J. Cremers, Gislin Dagnelie, Carel B. Hoyng, Arthur A. Bergen, Bart P. Leroy, Ronald J.E. Pennings, L. Ingeborgh van den Born, Caroline C.W. Klaver
Journal: Ophthalmology (2016)
Docetaxel rechallenge chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).
Authors: S. Bracarda, M. Sisani, M. Rossi, L. Galli, A. Hamzaj, S. Scali, V. De Angelis, A. Falcone
Journal: Journal of Clinical Oncology (2011)

e15145 Background: docetaxel-based chemotherapy (D-CT) represent the first line standard of care for mCRPC. Because no data exist about the most appropriate treatment duration, a matter of interest in mCRPC, we evaluated the possible advantages of a rechallenge chemotherapy approach. Methods: from July 2000 to March 2010 all consecutive patients treated with docetaxel for mCRPC in our institutions were evaluated for a possible rechallenge D-CT. In non-progressing cases, D-CT was interrupted either because PSA decreased by at least 90% or after a minimum of 6 cycles in the case of a PSA plateau. Median time to definitive progression (TTDP: defined for this protocol as the interval between the first D-CT infusion and the first evidence of definitive biochemical or clinical progression) was the primary end point of the study Results: data relate to the first 62 evaluated patients (median age 73 years; median Gleason score 7; median baseline PSA 53.0 ng/ml), 55 of whom achieved at least a stable disease after a median treatment duration of 4.8 months (m, range 0.8-9.1, disease control rate [DCR] 88.7%). After a median off-treatment period of 6.5m (range 1.6-27) all these 55 cases underwent a second round of D-CT because of a biochemical or clinical progression, and 33 responded (DCR 60.0%, median treatment duration 3.4m). After a further median off-treatment period of 4.6m, 26 patients underwent a third D-CT round and 10 responded (DCR 38.5%; median treatment duration 2.0m) with 6/10 starting, after a median off-treatment period of 3.1m a fourth D-CT round (2 responders). At a median follow-up of 23.9m, the median TTDP of the entire study population was 15.1 months (range 0.9-56.8). No grade 3/4 toxicities were observed. Conclusions: with a median TTDP of 15.1m, docetaxel rechallenge should be considered as a reasonable treatment option for mCRPC patients initially responding to D-CT. These results should be verified in controlled clinical trials.
Loss of Prostaglandin E Receptors During Progression of Rat Mammary Tumors From Hormonal Dependence to Autonomy&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: H Abou-Issa, J P Minton
Journal: JNCI Journal of the National Cancer Institute (1986)

Prostaglandin E (PGE) receptors and PGE-adenylate cyclase responsiveness were measured in tumor samples from a hormone-dependent subline of the transplantable MTW9 rat mammary tumor and from an autonomous subline derived from the hormone-dependent tumor. Scatchard analysis of the equilibrium binding data suggested that the hormone-dependent, slow-growing (MTW9A) tumors contain two major types of binding sites for PGE2: a high-affinity component (Kd<10−9M) and a low-affinity component [Kd>10−8M]. The hormone-autonomous, fast-growing tumors (MTW9D), however, have lost more than 80% of the PG binding sites and exhibited mainly a predominant PGE lower affinity component (Kd>10−8M). Loss of PGE receptors in autonomous tumors was not due to in vivo down-regulation of these receptors by excessive production of PGE, since both the hormone-dependent and autonomous tumors endogenously produce and release approximately the same amounts of PGE. Incubation of tumor tissues in vitro with PGE caused a significant stimulation of adenylate cyclase activity in the MTW9A tumors, whereas adenylate cyclase activity was not stimulated in the MTW9D tumors even in the presence of the nonhydrolyzable analogue of GTP, Gpp[NH]p. The results suggest that loss of PGE receptors and PGE-adenylate cyclase responsiveness occurs during progression of mammary tumors from hormonal dependence to autonomy and that the subsequent loss of cyclic AMP is associated with the uncontrolled growth characteristics of the autonomous tumors.
A systematic review of the safety and efficacy of parenteral estrogens in prostate cancer
Authors: R. Langley, G. Norman, M. Emmans Dean, Z. Hodges, G. Ritchie, K. Light, M. Sydes, M. Parmar, P. Abel, A. Eastwood
Journal: Journal of Clinical Oncology (2005)

4676 Background: The increasing and prolonged use of Luteinizing-Hormone Releasing Hormone (LHRH) analogues in the management of prostate cancer has highlighted concerns about long-term toxicity particularly osteoporosis. Oral estrogens are effective at producing castrate levels of testosterone but are not used because of cardiovascular (CVS) toxicity which has been attributed to first-pass hepatic metabolism. Administering estrogen through a transdermal patch should avoid CVS toxicity and osteoporosis. This review was undertaken to assess the safety and efficacy of parenteral estrogens in order to inform the design of a clinical trial. Methods: Eighteen electronic databases and appropriate paper and internet resources were searched for randomised-controlled trials comparing parenteral estrogen with other therapies in prostate cancer. Results: Seventeen trials were found. 9 assessed parenteral estrogens alone, 8 in combination with other treatments. The evidence was heterogeneous and some was of uncertain metholodogical quality. The majority of trials assessed intramuscular poyestradiol phosphate (PEP), no randomised evidence on the use of transdermal patches was found. PEP in a dose sufficient to produce castrate levels of testosterone, may be as effective as other hormonal treatments in controlling prostate cancer, measured in terms of disease-free and overall survival. At lower doses PEP was less effective. CVS mortality was not increased by the use of PEP alone compared to other hormonal treatments although the incidence of non-fatal CVS morbidity was increased. CVS toxicity was increased by the use of PEP in combination with low dose oral estrogen. Conclusions: There was insufficient evidence to determine the safety and efficacy of parenteral oestrogens conclusively. However, parenteral estrogen alone appears to be an effective treatment for prostate cancer with no associated increase in CVS mortality, although there may be an increase in non-fatal CVS morbidity. A randomized feasibility study comparing LHRH to transdermal estrogen is planned for men with locally advanced or metastatic prostate cancer. No significant financial relationships to disclose.
Relationship between hemoglobin (Hb) level drop and outcome of patients (pts) treated for small cell lung cancer (SCLC): Our retrospective analysis
Authors: L. Gianni, G. Genestreti, D. Tassinari, M. Papi, M. Imola, B. Rudnas, G. Monticelli, G. Oliverio, E. Pasquini, A. Ravaioli
Journal: Journal of Clinical Oncology (2004)

7271 Background: Anemia during chemo-radiotherapy negatively impacts treatment outcomes in a variety of tumor types. There is only one retrospective study that evaluate the relationship between Hb level and the outcome of pts treated with chemo-radiotherapy for SCLC (Jeyabalan et al: Proc ASCO 2003). Methods: A retrospective analysis of pts treated for SCLC between 1990 to 2003 was performed. We collected information about stage disease, chemo-radiotherapy performed, level of Hb at the start (Hbt0) and after three months (Hbt3) of treatment. The relationship between Hb level and pts outcome was analyzed with Fisher test analysis. Results: 104 pts were eligible. Median age was 63 years (range 44–81) with 44 (42.3%) limited disease, 59 (56.7%) extended disease and 1 (1%) missing. First-line chemotherapy was Cyclophosphamide/Epirubicin/Etoposide (CEVP-16) in 74 (71.2%) pts or Cisplatin/Etoposide (CVP-16) in 30 (28.8%) pts. 57 (54.8%) pts performed radiotherapy. At 3 months all pts performed at least 3 chemotherapy cycles (range 3–4). The Hbt0 was 13.35 gr/dl± 0.17 (media± ES) and the Hbt3 was 10.63 gr/dl± 0.16 (media± ES) with a difference of 2.7 gr/dl (IC95%=2.28–3.15). The Hb drop in CEVP-16 arm was 2.97± 0.28 gr/dl and 2.09± 0.39 in CVP-16 arm, with a p=0.068 at the Student t-test. Transfusions were required in 36 (34.6%) pts (median 3, range 1–9). We recorded 16 (15.4%) complete response, 47 (45.2%) partial response, 12 (11.5%) stable disease, 22 (21.2%) progression disease and 7 (6.7%) response not evaluated. 53 (51.1%) pts performed second-line chemotherapy. At today, 99 (95.2%) pts are died with a median survival of 348 days (Kaplan-Meyer analysis). Using Fisher test analysis, no statistical difference was find (p=0.462) in the relationship between the Hb level drop and the pts outcome. Conclusions: In this series the Hb level drop was common, but we did not find a statistical correlation between the level of anemia and the pts outcome. Prospective trials may offer insights on the relationship between anemia, chemo-radiotherapy and outcome of SCLC pts. Supported by Istituto Oncologico Romagnolo (IOR). No significant financial relationships to disclose.